Opioid Use Disorder in the Emergency Department

Gail D'Onofrio, MD, MS
Co-Lead Investigator

Yale University School of Medicine

David Fiellin, MD
Co-Lead Investigator

Yale University School of Medicine

The study uses a Hybrid Type 3 Effectiveness-Implementation framework and a modified stepped wedge design. The study will be conducted at four EDs with a high prevalence of patients with untreated opioid use disorder (OUD). The four sites will receive the same sequence of evaluations and interventions: the baseline evaluation period after the standard dissemination practice, the IF phase, and continuation of facilitation into the IF evaluation period. The timing of initiation of the study activities at each site will be randomly offset by ~ 3 month increments to accommodate logistical constraints of simultaneous implementation at all sites. The study populations will include (1) ED providers and staff involved in the treatment of patients with OUD; (2) Community opioid treatment provider and program staff involved in providing care for patients with OUD referred from the ED; and (3) ED patients with moderate to severe OUD.

This study is currently enrolling participants (as of May 2017).



Publications about CTN-0069 (NCT03023930)

NIDA protocol page


New England Consortium (Lead) search www
Greater New York search www
Mount Sinai Hospital
Mid-Atlantic search www
Johns Hopkins Hospital
Ohio Valley search www
University of Cincinnati Medical Center
Pacific Northwest search www
Harborview Medical Center

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 5/2017 --